Mast Therapeutics Inc  

(Public, NYSEMKT:MSTX)   Watch this stock  
Find more results for AMEX:ANX
0.625
+0.015 (2.46%)
Aug 29 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.60 - 0.62
52 week 0.40 - 1.10
Open 0.62
Vol / Avg. 531,283.00/572,453.00
Mkt cap 76.02M
P/E     -
Div/yield     -
EPS -0.23
Shares 121.63M
Beta 2.54
Inst. own 21%
Sep 9, 2014
Mast Therapeutics Inc at Rodman & Renshaw Global Investment Conference - 2:55PM EDT - Add to calendar
Aug 14, 2014
Mast Therapeutics Inc at Canaccord Genuity Growth Conference
Aug 11, 2014
Q2 2014 Mast Therapeutics Inc Earnings Release
Jun 19, 2014
Mast Therapeutics Inc Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -47.13% -42.03%
Return on average equity -55.70% -47.95%
Employees 21 -
CDP Score - -

Address

Suite 150, 12390 El Camino Real
SAN DIEGO, CA 92130
United States - Map
+1-858-5520866 (Phone)
+1-858-5520876 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease. As of December 31, 2011, the Company also is developing ANX-514, a detergent-free formulation of the chemotherapy drug docetaxel. The Company offers ANX-188 (purified poloxamer 188), ANX-514 (docetaxel for injectable emulsion) and Exelbine (vinorelbine injectable emulsion). In April 2011, the Company acquired SynthRx, Inc. In February 2014, Mast Therapeutics Inc completed its acquisition of Aires Pharmaceuticals, Inc. Aires became a wholly-owned subsidiary of Mast Therapeutics.

Officers and directors

Jack Lief Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Patrick L. Keran J.D. President, Chief Operating Officer, Secretary
Age: 42
Bio & Compensation  - Reuters
Brian M. Culley Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Brandi L. Roberts C.P.A Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Principal Financial Officer
Age: 40
Bio & Compensation  - Reuters
R. Martin Emanuele Ph.D Senior Vice President - Development
Age: 59
Bio & Compensation  - Reuters
Gregory D. Gorgas Senior Vice President - Commercial
Age: 51
Bio & Compensation  - Reuters
Santosh J. Vetticaden M.D., Ph.D. Chief Medical Officer and Senior Vice President
Age: 55
Bio & Compensation  - Reuters
Howard C. Dittrich M.D., F.A.C.C. Independent Director
Age: 56
Bio & Compensation  - Reuters
David A. Ramsay CPA Independent Director
Age: 49
Bio & Compensation  - Reuters
Lewis J. Shuster Independent Director
Age: 58
Bio & Compensation  - Reuters